US Government VC Investment?
- Recent STAT First Opinion essays have sparked debate on topics ranging from science funding to organ donation and vaccine policy.
- Allen, executive director of the Bayh-Dole coalition, contests a proposal to repeal the Bayh-Dole Act.
- In response to an article about the health consequences faced by two sisters who donated kidneys to their brother, Andy Howard, chairman of Kidney transplant Collaborative, expresses concern...
Explore expert opinions on critical issues related to science funding,organ donation,and vaccine policy. Joseph P. Allen, a key voice, contests the proposal to repeal the Bayh-Dole act, emphasizing its role in fostering economic growth and innovation as well as the many drugs and vaccines created with the act. Discover how this impacts the U.S. economy and job creation. Hear concerns about kidney donation narratives needing nuance, and a retired doctor’s warnings about vaccine approval policies. A biopharmaceutical veteran also shares his outlook regarding biomedical research funding. For insightful commentary, News Directory 3 has the latest. What’s next for these crucial discussions?
Experts Weigh In on science Funding, Organ Donation, and Vaccine Policy
Updated June 29, 2025
Recent STAT First Opinion essays have sparked debate on topics ranging from science funding to organ donation and vaccine policy. Letters to the editor offer diverse perspectives on these critical issues.
Joseph P. Allen, executive director of the Bayh-Dole coalition, contests a proposal to repeal the Bayh-Dole Act. The act allows academic research institutions,federal laboratories,and small companies to own and manage inventions they made from federally funded research. allen argues that the government isn’t equipped to function as a venture capitalist and that the Bayh-Dole Act has spurred important economic growth. He cites statistics showing that academic technology transfer enabled by the act has generated over 200 drugs and vaccines, 18,000 startups, $1 trillion in U.S. GDP, and 6.5 million jobs.
In response to an article about the health consequences faced by two sisters who donated kidneys to their brother, Andy Howard, chairman of Kidney transplant Collaborative, expresses concern that the piece presents an incomplete picture of living kidney donation. Howard acknowledges the family’s experience but emphasizes decades of clinical evidence demonstrating the safety and low risk of the procedure. He notes that more than a dozen people die each day waiting for a kidney transplant and that living donation is crucial to meeting the demand. Modern surgical advances and thorough pre-donation evaluations have drastically reduced risks, with mortality rates less than 1 in 10,000, according to recent studies.
Dina Stolman, a retired doctor, criticizes policies that create barriers to vaccine approval and use. She warns that these policies could lead to the resurgence of infectious diseases and unnecessary fatalities, endangering both the U.S. and global populations. Stolman calls for the medical community to advocate for public health and welfare.
Drew N. Kelner, a semi-retired veteran of the biopharmaceutical industry, emphasizes the potential impact of cuts to American biomedical research funding on the development of new medicines. Kelner fears that these cuts will curtail progress in treating various diseases and laments the possibility that future scientists may not have the same opportunities he had.
What’s next
These responses highlight the ongoing discussions surrounding science funding, healthcare, and public health policy. As these issues continue to evolve, further debate and collaboration will be essential to ensure continued progress and innovation.